FDA approves new formulation of HIV treatment drug

ABBOTT PARK, Ill. The Food and Drug Administration has approved a new formulation of an anti-retroviral drug for treating HIV made by Abbott, the drug maker announced.

The FDA approved a tablet form of the drug Norvir (ritonavir) in the 100 mg strength. The tablets, meant for use in combination with other anti-retroviral drugs to treat HIV, can be stored at room temperature and do not require refrigeration. The soft-gel capsule and liquid forms of the drug will remain available in the United States.

“Norvir has been a critical component of HIV treatment for many patients,” Abbott divisional VP infections disease development Scott Brun said in a statement. “The innovation behind the development of the Norvir tablet is the direct result of years of effort by Abbott scientists to address the needs of people living with HIV.”